A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

GLP-1 users are upping their purchases of frozen fruits (44%) and vegetables (40%) while reducing impulse purchases and larger meal portions. 80% of GLP-1 users expressed interest in trying frozen ...

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Linda Bethea details how the marketer of brands including Oikos and Silk is approaching emerging channels and artificial ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...